354 related articles for article (PubMed ID: 36158077)
1. Cisplatin for cancer therapy and overcoming chemoresistance.
Ranasinghe R; Mathai ML; Zulli A
Heliyon; 2022 Sep; 8(9):e10608. PubMed ID: 36158077
[TBL] [Abstract][Full Text] [Related]
2. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
4. Overcoming Chemotherapy Resistance in Germ Cell Tumors.
Országhová Z; Kalavska K; Mego M; Chovanec M
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625709
[TBL] [Abstract][Full Text] [Related]
5. Chemoresistance in Ovarian Cancer: Prospects for New Drugs.
Tendulkar S; Dodamani S
Anticancer Agents Med Chem; 2021; 21(6):668-678. PubMed ID: 32900355
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin's tumoricidal effect on human breast carcinoma MCF-7 cells was not attenuated by American ginseng.
Aung HH; Mehendale SR; Wang CZ; Xie JT; McEntee E; Yuan CS
Cancer Chemother Pharmacol; 2007 Feb; 59(3):369-74. PubMed ID: 16799811
[TBL] [Abstract][Full Text] [Related]
7. Retinoic acid receptor-beta prevents cisplatin-induced proximal tubular cell death.
Yago-Ibáñez J; García-Pastor C; Lucio-Cazaña FJ; Fernández-Martínez AB
Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165795. PubMed ID: 32278009
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy.
Dasari S; Njiki S; Mbemi A; Yedjou CG; Tchounwou PB
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163459
[TBL] [Abstract][Full Text] [Related]
9. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer.
Bortot B; Mongiat M; Valencic E; Dal Monego S; Licastro D; Crosera M; Adami G; Rampazzo E; Ricci G; Romano F; Severini GM; Biffi S
Int J Nanomedicine; 2020; 15():4793-4810. PubMed ID: 32764921
[TBL] [Abstract][Full Text] [Related]
11. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
12. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
13. Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma.
Hastings JF; Gonzalez Rajal A; Latham SL; Han JZ; McCloy RA; O'Donnell YE; Phimmachanh M; Murphy AD; Nagrial A; Daneshvar D; Chin V; Watkins DN; Burgess A; Croucher DR
Elife; 2020 Jun; 9():. PubMed ID: 32513387
[TBL] [Abstract][Full Text] [Related]
14. Phytocompounds from the Medicinal and Dietary Plants: Multi-target Agents for Cervical Cancer Prevention and Therapy.
Shoaib S; Islam N; Yusuf N
Curr Med Chem; 2022; 29(26):4481-4506. PubMed ID: 35232338
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin Chemotherapy and Cochlear Damage: Otoprotective and Chemosensitization Properties of Polyphenols.
Fetoni AR; Paciello F; Troiani D
Antioxid Redox Signal; 2022 Jun; 36(16-18):1229-1245. PubMed ID: 34731023
[No Abstract] [Full Text] [Related]
16. Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy.
Kryczka J; Kryczka J; Czarnecka-Chrebelska KH; Brzeziańska-Lasota E
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445588
[TBL] [Abstract][Full Text] [Related]
17. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review).
Wang G; Reed E; Li QQ
Oncol Rep; 2004 Nov; 12(5):955-65. PubMed ID: 15492778
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of miRNA in the perturbation of tumor immune microenvironment in chemoresistance: Therapeutic implications.
Mondal P; Kaur B; Natesh J; Meeran SM
Semin Cell Dev Biol; 2022 Apr; 124():99-113. PubMed ID: 33865701
[TBL] [Abstract][Full Text] [Related]
20. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
